VIR

#2065
Vir Biotechnology, Inc. - Common Stock
10.8 3 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
10.83
10.83
Jahresspanne
4.81
11.50
Tagesänderung
-4.24%
Monatliche Änderung
+21.01%
6 month change
+22.37%
Jahresänderung
+81.10%
Vorheriger Schlusskurs
11.3 1
Open
10.8 3
Tief
10.8 3
Hoch
10.8 3
Volumen
146
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Vir Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Vir Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K

Vir Biotechnology, Inc. current report, Q2 FY2025

Full document

Vir Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 29, 2025, details the results of Vir Biotechnology, Inc.'s 2025 Annual Meeting of Stockholders. The record date for the meeting was April 1, 2025, with 138,063,698 shares of common stock outstanding and entitled to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.

Material Changes and Voting Results

Stockholders voted on three proposals at the Annual Meeting:

  • Proposal 1: Election of Directors - Stockholders elected Jeffrey S. Hatfield and Saira Ramasastry as Class III directors to serve until the 2028 Annual Meeting.
    • Jeffrey S. Hatfield: 93,985,116 votes For; 10,933,739 votes Withheld; 12,050,291 Broker Non-Votes.
    • Saira Ramasastry: 98,467,755 votes For; 6,451,100 votes Withheld; 12,050,291 Broker Non-Votes.
  • Proposal 2: Advisory Vote on Executive Compensation - Stockholders approved the compensation of named executive officers.
    • Results: 100,486,810 votes For; 4,280,297 votes Against; 151,748 Abstentions; 12,050,291 Broker Non-Votes.
  • Proposal 3: Ratification of Independent Registered Public Accounting Firm - Stockholders ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2025.
    • Results: 116,311,775 votes For; 162,660 votes Against; 494,711 Abstentions; 0 Broker Non-Votes.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of voting results.

Key Facts for Investor Verification

  • Confirmation that Jeffrey S. Hatfield and Saira Ramasastry have assumed their roles as Class III directors.
  • Verification of the high approval rate for executive compensation (approximately 95.7% of votes cast).
  • Confirmation that Ernst & Young LLP remains the independent auditor for the 2025 fiscal year.
  • Review of the significant number of broker non-votes (12,050,291) on director elections and executive compensation.

Nachrichten